This finding is supported by increased serum levels of CD4+ and CD8+ T cells as well as interferon-γ in patients with TP53-mutated tumors treated with decitabine + R-CHOP [31], noting that TP53-mutated DLBCL tumors demonstrate decreased interferon signaling as well as decreased upregulation of CD8+ T cells [33]. Here, TP53 is linked to diffuse large B-cell lymphoma.